Brokers Issue Forecasts for Zoetis Inc.’s FY2017 Earnings (ZTS)
Zoetis Inc. (NYSE:ZTS) – Equities research analysts at William Blair increased their FY2017 earnings estimates for shares of Zoetis in a report released on Wednesday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $2.34 per share for the year, up from their prior estimate of $2.31. William Blair also issued estimates for Zoetis’ Q4 2017 earnings at $0.66 EPS, FY2018 earnings at $2.64 EPS, FY2019 earnings at $2.92 EPS and FY2020 earnings at $3.23 EPS.
Other equities analysts have also issued reports about the company. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a report on Wednesday, May 10th. Jefferies Group LLC upped their target price on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. BMO Capital Markets reaffirmed a “buy” rating and set a $60.00 target price on shares of Zoetis in a report on Thursday, May 4th. Argus reaffirmed a “buy” rating and set a $69.00 target price (up from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, CL King started coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $64.78.
TRADEMARK VIOLATION NOTICE: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/10/brokers-issue-forecasts-for-zoetis-inc-s-fy2017-earnings-zts.html.
Shares of Zoetis (NYSE:ZTS) opened at 60.81 on Thursday. The firm’s 50-day moving average price is $62.40 and its 200-day moving average price is $57.94. The firm has a market capitalization of $29.85 billion, a PE ratio of 35.35 and a beta of 1.02. Zoetis has a 52-week low of $46.86 and a 52-week high of $63.85.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 64.16% and a net margin of 17.50%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.49 EPS.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be given a dividend of $0.105 per share. The ex-dividend date is Tuesday, June 13th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.69%. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.
In other news, insider Catherine A. Knupp sold 5,785 shares of the stock in a transaction on Friday, May 12th. The stock was sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the sale, the insider now owns 24,415 shares in the company, valued at approximately $1,468,806.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. increased its stake in shares of Zoetis by 13.2% in the fourth quarter. Macquarie Group Ltd. now owns 144,492 shares of the company’s stock worth $7,734,000 after buying an additional 16,860 shares during the period. CENTRAL TRUST Co increased its stake in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares during the period. Fulton Bank N.A. increased its stake in shares of Zoetis by 35.8% in the first quarter. Fulton Bank N.A. now owns 5,554 shares of the company’s stock valued at $296,000 after buying an additional 1,463 shares during the period. Raymond James Trust N.A. increased its stake in shares of Zoetis by 24.6% in the first quarter. Raymond James Trust N.A. now owns 10,465 shares of the company’s stock valued at $559,000 after buying an additional 2,063 shares during the period. Finally, Gulf International Bank UK Ltd increased its stake in shares of Zoetis by 1.5% in the first quarter. Gulf International Bank UK Ltd now owns 145,165 shares of the company’s stock valued at $7,747,000 after buying an additional 2,100 shares during the period. Institutional investors own 94.51% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.